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ABSTRACT
Management of ovarian cancer still requires improvements in therapeutic 
options. A drug delivery strategy was tested that allows specific targeting of tumor 
cells in combination with a controlled release of a cytotoxic molecule. To this aim, the 
efficacy of a loco-regional intraperitoneal treatment with a bioconjugate (ONCOFID-S) 
derived by chemical linking of SN-38, the active metabolite of irinotecan (CPT-11), to 
hyaluronan was assessed in a mouse model of ovarian carcinomatosis. 
In vitro, the bioconjugate selectively interacted with ovarian cancer cells through 
the CD44 receptor, disclosed a dose-dependent tumor growth inhibition efficacy 
comparable to that of free SN-38 drug, and inhibited Topoisomerase I function 
leading to apoptosis by a mechanism involving caspase-3 and -7 activation and PARP 
cleavage. In vivo, the intraperitoneal administration of ONCOFID-S in tumor-bearing 
mice did not induce inflammation, and evidenced an improved therapeutic efficacy 
compared with CPT-11.
In conclusion, SN-38 conjugation to hyaluronan significantly improved the profile 
of in vivo tolerability and widened the field of application of irinotecan. Therefore, 
this approach can be envisaged as a promising therapeutic strategy for loco-regional 
treatment of ovarian cancer. 
INTRODUCTION 
Ovarian cancer (OC) represents a serious clinical 
entity, with estimated 21,980 new cases and 14,270 deaths 
in U.S. in 2014 [1]. The vast majority of patients with 
epithelial OC tends to present with advanced stage disease, 
when it has already metastasized throughout the peritoneal 
cavity and to the upper abdomen, resulting in a low 
overall cure rate and high percentage of chemoresistance 
[2]. Hence, new therapeutic approaches are imperatively 
needed, in particular an efficient drug delivery strategy 
capable of targeting highly disseminated and aggressive 
tumor cells. This task can be accomplished by exploiting 
cancer-specific receptors and the related ligands, CD44 
and hyaluronic acid (HA) representing a notable example. 
HA is a linear polysaccharide naturally present in 
the extracellular matrix, the synovial fluid of joints and 
the cartilage and hence fully biocompatible [3, 4]. HA 
is the primary ligand for CD44, that is overexpressed in 
many cancer types including the ovarian histotype [5]. 
Therefore, the conjugation of a drug to hyaluronan can 
confer specificity and selectivity for cancerous cells, 
and can also provide a pharmacological advantage in 
terms of solubilization and stabilization. This feature 
is of inestimable value for those drugs whose high 
hydrophobicity precludes the clinical use, as in the case 
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of the active metabolite SN-38 of the pro-drug irinotecan 
(CPT-11), which is about 100-fold more potent than its 
precursor [6]. The direct administration of SN-38 could 
overcome the limitations due to the irinotecan metabolism 
that is quite inefficient (approximately only 10% of 
irinotecan is converted to SN-38) and characterized by a 
considerable patient-to-patient variability. Interestingly, 
while irinotecan is usually employed in colon cancer, it 
has been recently used with success also against ovarian 
cancer, in particular in those cases refractory to paclitaxel 
and carboplatin, the first-line post-operative treatment 
option [7-9]. 
Several approaches are currently under investigation 
to allow SN-38 administration, among which inclusion 
into nanoparticles [10], liposomes [11] and micelles [12], 
and conjugation with polyamidoamine dendrimers [13] or 
carbohydrates [2].
Here, we report that a bioconjugate based on 
the chemical linking of SN-38 to HA (ONCOFID-S) 
retains a comparable activity respect to the free drug in 
vitro, but performs better in vivo in OC xenograft mouse 
models compared to the CPT-11 pro-drug. Moreover, the 
bioconjugate significantly improves the tolerability profile 
of the local treatment. These results make ONCOFID-S a 
promising drug for the loco-regional treatment of ovarian 
cancer, thus supporting its testing in a clinical setting.
RESULTS
Evaluation of HA receptor expression
CD44 and RHAMM are considered the main 
receptors for hyaluronan binding. The expression of these 
receptors in IGROV-1, OVCAR-3 and SKOV-3 tumor cell 
lines was analyzed by flow cytometry. CD44 was intensely 
expressed in all cell lines tested, whereas RHAMM was 
mildly present only at intracellular level with the exception 
of OVCAR-3 that exhibited also a weak extracellular 
expression (Fig. S1).
Analysis of interaction of ONCOFID-S with 
target cancer cell lines
The role played by CD44 in the interaction between 
cells and the bioconjugate was assessed in a competition 
assay where target cancer cell lines were incubated with an 
anti-CD44 blocking mAb, and then with BODIPY-labeled 
ONCOFID-S. The blocking antibody induced a shift in 
the cell-bound fluorescent signal as compared to the 
cells incubated with the bioconjugate only (Fig. 1), thus 
demonstrating the pivotal role of CD44 in the interaction 
of the hyaluronan-based bioconjugate with tumor cells. 
ONCOFID-S inhibits Topo I activity and induces 
apoptosis 
SN-38 is the active metabolite of irinotecan and 
interacts specifically with the enzyme Topo I, blocking its 
property to relieve torsional strain in DNA by inducing 
reversible single-strand breaks. To evaluate the effect 
of ONCOFID-S and SN-38 on Topo I activity, nuclear 
protein extracts from treated cells were incubated with a 
supercoiled plasmid DNA (pBR322) and the ratio between 
the supercoiled and relaxed forms was visualized (Fig. 
2A) and quantified (Fig. 2B) by gel electrophoresis. In all 
tumor cell lines, both the bioconjugate and the free drug 
presented the same inhibitory activity towards Topo I, thus 
indicating that the active SN-38 molecules are released by 
ONCOFID-S and have access to the nucleus where they 
can block the enzyme activity. 
Irinotecan has been previously reported to be 
capable of activating apoptosis [14]. To assess the capacity 
Figure 1: Blocking of the bioconjugate/receptor interaction by an anti-CD44 antibody. IGROV-1, OVCAR-3 and SKOV-3 
tumor cell lines were incubated with BODIPY-labeled ONCOFID-S alone (solid line) or in the presence of an anti-CD44 blocking mAb 
(dashed line), and analyzed by flow cytometry. Grey plot depicts isotype control. Data at the upper-right corner of each panel report the 
percentage of reduction induced by anti-CD44 mAb blocking treatment.
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Figure 3: Apoptosis induction by free and conjugated drug. (A) IGROV-1, OVCAR-3 and SKOV-3 cell lines were incubated 
with ONCOFID-S (dotted line) or free SN-38 (solid line) for 6 hours and stained with a fluorescent probe detecting active caspase 3 and 
7. (B) After a 12-hour treatment with ONCOFID-S (dotted line) or free SN-38 (solid line), the same ovarian cancer cell lines were labeled 
with a FITC-conjugated anti-cleaved PARP mAb. Grey plot depicts isotype control.
Figure 2: Assessment of bioconjugate mechanism of action. (A) Inhibition of Topoisomerase I activity after ONCOFID-S or 
SN-38 treatment in IGROV-1, OVCAR-3 and SKOV-3 cell lines. Gels show the supercoiled or relaxed forms of pBR322 plasmid after 
incubation with a 1:100 dilution of nuclear protein neat extracts obtained from tumor cells treated with conjugated or free drug for 4 hours. 
Marker; lane 1, relaxed pBR322 plasmid (positive control); lane 2, supercoiled plasmid (negative control); lane 3, supercoiled plasmid 
in the presence of nuclear protein neat extract from drug-untreated cells; lane 4, supercoiled pBR322 admixed with nuclear protein neat 
extract from ONCOFID-S-treated cells; lane 5, supercoiled pBR322 admixed with nuclear protein neat extract from SN-38-treated cells. 
(B) The quantification of the reaction shown in A. Figure reports mean ± SD of 3 independent experiments.
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of the bioconjugate to induce apoptosis as well, the 
activation of caspase 3 and 7 and the cleavage of PARP 
were evaluated on target cells. Tumor cell lines were 
incubated with ONCOFID-S or SN-38, and stained with 
a fluorochrome-labeled probe that binds covalently to 
the active caspase 3 and 7 or a FITC-labeled anti-human 
cleaved PARP mAb. Cytometry analysis disclosed that 
both treatments induced similar activation of caspase 
cascade and similar levels of cleaved PARP (Fig. 3), 
leading to overlapping effects on apoptosis induction.
Tumor cell growth inhibitory activity of 
ONCOFID-S
To test ONCOFID-S activity, IGROV-1, OVCAR-3 
and SKOV-3 target cell lines were incubated with 
escalating concentrations of the bioconjugate and the dose-
dependent growth inhibitory activity was compared to 
that of the free irinotecan metabolite. IC50 of ONCOFID-S 
was comparable to that observed for SN-38 (Table S1). 
No toxic effect could be ascribed to hyaluronan (data not 
shown).
Effects on the peritoneal lining
In a clinical setting, locally administered antitumor 
therapy must be well tolerated. To assess whether 
ONCOFID-S induced irritating effects on the peritoneal 
mesothelial lining, three groups of BALB/c mice were 
injected once i.p. with the bioconjugate, CPT-11 or SN-
38. Samples of the abdominal wall were then collected 
at different time points after treatment and analyzed 
histologically (Fig. 4 and Fig. S2). In particular, in 
ONCOFID-S-treated mice, mesothelium did not show 
inflammatory infiltrates or morphological alterations 
at any time. Conversely, SN-38 brought about a strong 
inflammatory reaction at both the mesothelial lining and 
the muscle abdominal wall, which was already evident 
after 24 hours and became more pronounced the following 
days. 
ONCOFID-S inhibits OC tumor growth in vivo 
and prolongs survival of treated mice
The in vivo antitumor therapeutic activity of 
ONCOFID-S was evaluated in mice bearing OC 
xenografts. SCID mice were inoculated i.p. with 
IGROV-1 or SKOV-3 cell lines, and treated locally with 
ONCOFID-S or the free CPT-11 through the i.p. route. We 
administered the precursor irinotecan instead of its active 
metabolite because of poor water solubility, high side 
effects and instability of SN-38 at a physiological pH [15], 
factors that limit its clinical use. The therapeutic impact of 
the different treatments was evaluated by bioluminescence 
Figure 4: Local tolerability study. Histological analysis were carried out on peritoneal mesothelial lining at different time points (8 
hours, 24 hours, 4 days and 7 days) after i.p. injection of SN-38 or ONCOFID-S. (H&E staining; original magnification, x10).
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imaging. 
Results of a pilot study carried out with mice 
engrafted with SKOV-3 cells showed that ONCOFID-S 
loco-regional treatment had a relevant inhibitory effect on 
their growth as compared to untreated as well as CPT-11-
treated mice (p = 0.03 and p = 0.05, respectively; Fig. 5A). 
When the bioconjugate was tested in IGROV-1-bearing 
mice in a confirmatory experiment, ONCOFID-S not 
only disclosed a strong antitumor activity vs. controls (p 
= 0.004; Fig. 5B), but resulted even more effective than 
CPT-11 (p = 0.05). 
These results were confirmed by survival analysis 
in IGROV-1-bearing mice. Indeed, ONCOFID-S treated 
animals (median survival, 71 days) underwent a strong 
therapeutic effect and presented an increased survival 
compared to both untreated control mice (median survival, 
22 days; p = 0.001) and CPT-11-treated animals (median 
survival, 66 days; p = 0.004; Fig. 5B, right panel). 
DISCUSSION
Irinotecan is a synthetic derivative of camptotecin 
and a FDA-approved drug for the treatment of colorectal 
carcinoma. It has been also showed to potentially 
represent a promising drug for ovarian cancer, in both 
preclinical [16] and clinical studies [17]. In particular, 
it has been advanced in cases of platinum- and taxane-
resistant and refractory disease, a clinical setting where 
chemotherapy options are very limited. However, it 
should be noted that only few papers relate to the use of 
irinotecan as a single agent [17-19], while the majority 
reports the association of irinotecan with other drugs, such 
as docetaxel [9], etoposide [20] and cisplatin [21, 22], 
thus making difficult to discriminate the contribution of 
each drug to the outcome described. Noteworthy, all these 
clinical studies involved the administration of the drug by 
the i.v. route, with significant (up to grade 3 and 4) adverse 
events such as leukopenia, thrombocytopenia and diarrhea 
[23]. A loco-regional administration of irinotecan is quite 
uncommon, despite the fact that the carboxylesterase 
enzymes responsible for the conversion of the pro-drug 
to the active SN-38 metabolite are present also in the 
peritoneum [24, 25]. This is of particular interest in the 
case of ovarian cancer; in fact, due to the lack of reliable 
screening tests and to the non-specificity of signs and 
symptoms, the vast majority of epithelial ovarian cancer 
patients presents at a diagnosis with an advanced stage 
disease, mainly involving the peritoneum. This condition, 
usually seen as dismal, could potentially benefit of a highly 
aggressive loco-regional therapy. Indeed, the peritoneum-
plasma barrier represents a drawback for pharmacological 
treatments given i.v., but on the other hand can sustain a 
local delivery of even high concentrations of drugs, thus 
reducing and sparing heavy systemic side effects. In this 
regard, the association of cytoreductive surgery (CS) with 
hyperthermic intraperitoneal chemotherapy (HIPEC) has 
proved to be effective in improving survival [26]. 
Here, we presented a drug delivery system 
involving the use of a HA-based bioconjugate that has 
the potentiality to improve the loco-regional treatment 
of OC, in particular in terms of safety and tolerability. 
Despite clinical successes in fact, CS plus HIPEC remains 
a great challenge for both clinicians (a particular technical 
expertise is required) and patients (great morbidity, 
complications such as intraperitoneal adhesions, infections 
etc.), so that only patients with good performance status 
Figure 5: Assessment of in vivo tumor growth and response to therapy. Bioluminescence imaging of treated or untreated mice 
inoculated with 5 x 106 bioluminescent SKOV-3 (A) or IGROV-1 (B) cells. Panels show three representative mice per group at 25 days 
after tumor injection. The vertical box plot represented the cumulative total photons emission from mice treated or untreated at day 25. Six 
mice per group were analyzed and data represent means ± SD. Kaplan-Meier survival curves of mice inoculated with IGROV-1 (B) cells 
and treated with ONCOFID-S (OF-S; open circles), CPT-11 (filled triangle) or untreated (UT; filled circles).
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can be candidates for this procedure [26]. 
We previously showed that a paclitaxel-HA 
conjugate exerted a relevant therapeutic activity against 
OC in a preclinical setting [27], and was also very efficient 
towards bladder cancer both in experimental [28, 29] and 
clinical conditions [30]; moreover, ONCOFID-S has been 
already successfully tested in a mouse model of colorectal 
peritoneal carcinomatosis [6], thus prompting us to assess 
its potential therapeutic use for OC. 
In addition to its well-known biocompatibility, 
hyaluronan can act as a suitable carrier being endowed 
with the capability to selectively target tumor cells through 
the binding to CD44. This receptor is over-expressed in 
many cancers, including the ovarian histotype. Indeed, 
such selectivity of ONCOFID-S was confirmed by 
competition studies with an anti-CD44 blocking mAb. 
Importantly, the chemical linking of SN-38 to HA did not 
impact the activity of the drug, as demonstrated by the 
ability of ONCOFID-S to inhibit in vitro Topo I function 
and to induce apoptosis in ovarian cancer cells, effects 
that were similar to those exerted by the free molecule. 
In turn, these features present an important practical 
follow-out on the anti-tumor efficacy in vitro and also in 
vivo, both shortly after the drug administration schedule 
has been completed when assessing tumor growth by 
imaging, and long-term when considering survival. In 
fact, the bioconjugate significantly reduced the short-term 
tumor burden in both SKOV-3- and IGROV-1-engrafted 
mice, performing even better than CPT-11. Moreover, 
ONCOFID-S significantly prolonged survival of IGROV-
1-induced peritoneal carcinomatosis respect to the related 
free drug.
Apart such therapeutic successes, the conjugation 
with HA brings about additional relevant advantages. 
From a pharmacological point of view, it drastically 
increases the water solubility of SN-38 thus allowing 
its direct administration. In this regard in fact, SN-38 
is at least 100-fold more active in vitro than CPT-11 at 
equimolar concentrations, but its clinical use is precluded 
because of the intrinsic toxicity and extremely low water 
solubility [6]. Moreover, it has been shown that HA has 
per se the capacity to reduce postoperative and disease-
related adhesions without impacting the metastatic 
potential of tumor cells [31]. From a clinical point of 
view, the therapeutic outcome can be achieved with 
negligible adverse effects. Indeed, histological analysis 
clearly disclosed that the bioconjugate was completely 
devoid of local toxicity, in line with previously reported 
data [6, 27], while free SN-38 was strongly inflammatory. 
In addition, ONCOFID-S has been reported not to cause 
myelotoxicity, thus potentially representing an attractive 
candidate for the treatment of UGTA1 genotype patients, 
who are prone to develop severe neutropenia related to 
CPT-11 [6].
Overall, present data envisage that the conjugation 
with HA can provide a strategy to potentially improve the 
loco-regional treatment of OC, and to widen the use of 
existing drugs over their formal approval, thus increasing 
the portfolio of potential therapeutic options.
MATERIALS AND METHODS
Drugs
The hyaluronan-SN-38 bioconjugate, (ONCOFID-S, 
Fidia Farmaceutici, Abano Terme, Italy), has been 
previously described [6]. The batch of ONCOFID-S used 
was characterized by a SN-38 loading of 9.4%. Irinotecan 
(CPT-11) and SN-38 were purchased from Antibioticos 
(Rodano, Italy). When needed, bioconjugate was 
labeled with the fluorochrome BODIPY TR cadaverine 
(Invitrogen, San Giuliano Milanese, Italy), as previously 
described [27].
Tumor cell lines
The following human ovarian cancer cell lines 
were used: IGROV-1, OVCAR-3 and SKOV-3. Cells 
were grown in RPMI 1640 (EuroClone, Milan, Italy) 
supplemented with 10% (v/v) heat-inactivated fetal bovine 
serum (Gibco BRL, Paisley, UK), 2 mM L-glutamine 
(Gibco BRL), 10 mM HEPES (PAA Laboratories, Linz, 
Austria), 200 U/mL penicillin (Pharmacia & Upjohn, 
Milan, Italy), 200 U/mL streptomycin (Bristol-Mayers 
Squibb Italia, Rome, Italy) and 1 mM sodium pyruvate 
(Lonza, Basel, Switzerland), hereafter referred as to 
complete medium. Cell lines were maintained at 37°C in 
a humidified atmosphere containing 5% CO2.
Viability assay
The determination of in vitro drug cytotoxicity 
was assessed by the ATPlite luminescence adenosine 
triphosphate (ATP) detection assay system (PerkinElmer, 
Zaventem, Belgium), according to the manufacturer’s 
instructions. All ovarian cancer cell lines were 
resuspended in complete medium and seeded into 96-well 
flat-bottomed plates (8 x 103/well). The day after, different 
concentrations of drugs were added (final volume, 100 
µL/well) for 72 hours. At day 4, 50 µL of lysis solution 
were added to each well followed by addition of 50 µL of 
substrate solution. Finally, the luminescence was counted 
by the TopCount Microplate Counter (PerkinElmer). 
Within each experiment, determinations were performed in 
triplicate and experiments were repeated 5 times for each 
cell line. The percentage of cell survival was calculated by 
determining the counts per second (cps) values according 
to the formula: [(cpstested - cpsblank) / (cpsuntreated control - 
cpsblank)] x 100, with cpsblank referring to the cps of wells 
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that contained only medium and ATPlite solution. The 
IC50 values were calculated from semi-logarithmic dose-
response curves by linear interpolation.
Flow cytometry analysis
CD44 and CD168 (RHAMM) expression in 
all tumor cell lines was evaluated by flow cytometry, 
as previously detailed [27]. Direct interaction of 
ONCOFID-S with cancer cell lines was assessed by 
incubating cells with BODIPY-labeled bioconjugate (6 
µg/ml in SN-38 equivalent) for 30 minutes in the presence 
of an anti-CD44 blocking mAb (10 µg/ml, clone 5F12, 
Lifespan Biosciences, Seattle, WA). Apoptosis induction 
was evaluated in terms of activation of the caspases 3 
and 7, as previously reported [29], and by determining 
the percentage of the cleaved form of poly ADP-ribose 
polymerase (PARP). In this case, ovarian cancer cell 
lines were incubated with free SN-38 (50 µg/mL) or 
ONCOFID-S (50 µg/ml in SN-38 equivalent) for 12 hours 
at 37°C, washed twice, and labeled with FITC-conjugated 
anti-cleaved PARP mAb (Becton Dickinson, Franklin 
Lakes, NJ). All experiments were carried out using a flow 
cytometer FACS-Calibur (Becton Dickinson) and the 
FlowJo 7.6.5 data analysis software package (TreeStar, 
USA).
Assessment of Topoisomerase I activity by 
plasmid DNA relaxation assay 
Topoisomerase I (Topo I) was isolated from tumor 
cell lines by Qproteome Nuclear Protein Kit (Qiagen, 
Milan, Italy), after incubation of cells (5 x 106/sample) 
with ONCOFID-S (50 μg/mL in SN-38 equivalents), 
SN-38 (50 μg/mL) or complete medium (untreated cells) 
at 37°C for 1 hour. Enzyme activity was assessed using 
the Human Topo I Assay Kit for cell extracts (Inspiralis, 
Norwich, United Kingdom). Dilutions of cell extracts 
(1:5, 1:10, 1:50, 1:100 and 1:500) were incubated for 
30 minutes at 37°C with the relaxation mix containing 
a supercoiled DNA substrate (pBR322). Reaction was 
stopped by adding an equal volume of chloroform/
isoamyl alcohol (24:1). Samples were fractionated by 
0.8% agarose gel electrophoresis, visualized by ethidium 
bromide staining and quantified by UV densitometry using 
the supercoiled and relaxed pBR322 plasmid as positive or 
negative control, respectively. Inhibition of Topo I activity 
was calculated as the ratio between the supercoiled 
fractions in treated cells and the positive control and 
expressed as percentage.
Mice
Six to eight week-old female severe combined 
immunodeficiency (SCID) and BALB/c mice were 
purchased from Charles River Laboratories (Calco, Italy), 
and housed in our Specific Pathogen Free (SPF) animal 
facility. Procedures involving animals and their care were 
in conformity with institutional guidelines (D.L. 116/92 
and subsequent implementing circulars), and experimental 
protocols (project ID: 3/2012) were approved by the local 
Ethical Committee of Padua University (CEASA). During 
in vivo experiments, animals in all experimental groups 
were examined daily for a decrease in physical activity 
and other signs of disease or drug toxicity; severely ill 
animals were euthanized by carbon dioxide overdose.
Local tolerability analysis
To assess the potential irritating effect of 
bioconjugate and free drug on peritoneal mesothelium, 
BALB/c mice were injected once i.p. with 200 mg/
kg (19.2 mg/kg in SN-38 equivalents) of ONCOFID-S, 
60 mg/kg of CPT-11 or 19.2 mg/kg of SN-38 (8 mice/
group). At different time points thereafter (8 hours, 24 
hours, 4 days and 7 days), two animals per time point 
were sacrificed and fragments of their abdominal wall 
were collected for morphological analysis. For histologic 
evaluation, tissue samples were fixed in 4% neutral-
buffered formalin, embedded in paraffin, sectioned at 4 
µm and stained with hematoxylin and eosin.
Anti-tumor activity in vivo and optical imaging
SCID mice were inoculated i.p. with 5 x 106 
IGROV-1 or SKOV-3 tumor cells. Pharmacological 
treatments were started at day 7 from cancer cell 
lines injection and carried out according to a q7dx3 
schedule (every 7 days for 3 doses). Each experiment 
comprised groups of animals (six mice/group) that 
received ONCOFID-S i.p. (200 mg/kg, 19.2 mg/kg in 
SN-38 equivalents), CPT-11 i.p. (60 mg/kg), or were 
left untreated. Injected tumor cells had been previously 
transduced with a lentiviral vector coding for the firefly 
luciferase reporter gene [32] to track tumor growth in vivo. 
Bioluminescence (BLI) images were acquired at different 
time points after in vivo cell injection using the IVIS 
Lumina II Imaging System (PerkinElmer). Ten minutes 
before each imaging session, animals were anesthetized 
with isoflurane/oxygen and administered i.p. with 150 
mg/kg of D-luciferin (PerkinElmer) in Dulbecco’s 
Phosphate-Buffered Saline (DPBS). A constant region of 
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interest (ROI) was manually selected around the abdomen 
of animals and the signal intensity was measured as 
radiance (photon/sec) using the LivingImage software 
3.2 (PerkinElmer). Tumor growth and response to therapy 
were monitored by BLI and by recording survival. 
Statistical analysis
Survival curves and probabilities were estimated 
using the Kaplan-Meier technique. A log-rank test for 
comparisons or an Anova test were used when required. 
Analysis of data were done using the MedCalc (version 
12) and SigmaPlot (version 12.3) statistical packages.
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